Rheumatology Indications

SIMPONI (golimumab) was developed to fit with patient needs and lifestyle, while continuing to improve functionality and disease outcomes. It is the first and only subcutaneous anti-tumour necrosis factor (TNF) therapy with convenient once-monthly dosing from day one, licensed for Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-Axial SpA) and Psoriatic Arthritis (PsA) within Rheumatology.1

SIMPONI® (golimumab): requires fewer injections under the skin than any currently available sub-cutaneous anti-TNF biologic medicine, from day one.1

SmartJect® Features

  1. 1. Hidden needle

Thin needle automatically deploys (first click), then retracts (second click), so your patients never have to see it.

  1. 2. Green safety sleeve

Interlock prevents operation until the device is firmly pressed against injection site.

  1. 3. Activation button

Patients press the raised part of the button to start the injection.

  1. 4. Large viewing window

It easy to see when the full dose of SIMPONI has been administered.

  1. 5. Expiration date

Printed on the side of the autoinjector.

  1. 6. Easy-to-grip shape

Designed with patients in mind, with an easy-to-grip, oval-shaped body.

Dosage and administration

Refer to the Summary of Product Characteristics for further details on indications and dosing.1

SIMPONI should be injected subcutaneously (SC). Treatment should be initiated under the supervision of a physician experienced in the diagnosis and treatment of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-Axial SpA) or UC. Patients may self-inject, if comfortable doing so after instruction.

Rheumatoid Arthritis (RA): 50 mg given once a month, on the same date each month, concomitantly with MTX. Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-Axial SpA): 50 mg given once a month, on the same date each month. Clinical response is usually achieved within 12-14 weeks of treatment (3 or 4 doses). Continued therapy should be reconsidered in patients showing no evidence of therapeutic benefit within this time period.

Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-Axial SpA): For patients weighing > 100 kg who do not achieve an adequate clinical response after 3 or 4 doses, consideration may be given to increasing the dose to 100 mg once a month, taking into account the increased risk of certain serious adverse reactions with the 100 mg dose compared with the 50 mg dose.1

IE-GOL-00048|Date of preparation: November 2020